Daptomycin: pharmacology and clinical use

被引：39

作者：

Kosmidis, Christos ^{[1
]}

Levine, Donald P. ^{[1
]}

机构：

[1] Wayne State Univ, Univ Hlth Ctr, Dept Med, Detroit, MI 48201 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期

关键词：

daptomycin; Gram-positive infections; pharmacology; resistance; RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITIES; ACUTE-RENAL-FAILURE; ENTEROCOCCAL BACTEREMIA; COMPLICATED SKIN; REDUCED SUSCEPTIBILITY; BACTERICIDAL ACTIVITY; ANTIMICROBIAL AGENTS; VANCOMYCIN; EXPERIENCE;

D O I：

10.1517/14656561003598893

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered in this review: Literature from 1986 to present was reviewed for pharmacological, preclinical and clinical studies on daptomycin. What the reader will gain: The pharmacological properties, resistance mechanisms and clinical applications of daptomycin are discussed. Recommendations are offered on the use of this agent for the treatment of resistant Gram-positive infections. Take home message: Daptomycin is a reliable agent for the treatment of Gram-positive infections. It has been shown to be effective in bacteremia and endocarditis, as well as in soft-tissue infections caused by Gram-positive organisms. Its role in the treatment of bone and joint infections is not well-defined. Resistance is currently uncommon in clinical isolates. However, emergence of resistance during therapy is a concern. This may be prevented by use of higher doses.

引用

页码：615 / 625

页数：11

共 79 条

[1] Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection
Alder, J
Li, TC
Yu, DH
Morton, L
Silverman, J
Zhang, XX
Critchley, I
Thorne, G
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3561 - 3566
[2] [Anonymous], 47 ANN M INF DIS SOC
[3] Clinical Experience With Daptomycin in Patients With Orthopedic-Related Infections
Antony, Suresh J.
Angelos, Erin
Stratton, Charles W.
[J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2006, 14 (03) : 144 - 149
[4] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
Arbeit, RD
Maki, D
Tally, FP
Campanaro, E
Eisenstein, BI
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) : 1673 - 1681
[5] Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
Benvenuto, Mark
Benziger, David P.
Yankelev, Sara
Vigliani, Gloria
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) : 3245 - 3249
[6] Cost-Effectiveness of Daptomycin versus Vancomycin and Gentamicin for Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and/or Endocarditis
Bhavnani, S. M.
Prakhya, A.
Hammel, J. P.
Ambrose, P. G.
[J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) : 691 - 698
[7] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens
Carpenter, CF
Chambers, HF
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) : 994 - 1000
[8] Daptomycin dose-effect relationship against resistant gram-positive organisms
Cha, R
Grucz, RG
Rybak, MJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) : 1598 - 1603
[9] Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
Chakraborty, Abhijit
Roy, Sandip
Loeffler, Juergen
Chaves, Ricardo L.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (01) : 151 - 158
[10] In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species
Citron, Diane M.
Appleman, Maria D.
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (10) : 3814 - 3818

← 1 2 3 4 5 6 7 8 →